Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan J Thompson

Showing results (171-180 of 200) with videos related to

Pageof 20
Sort By:
Neuroimage. Clinical|December 7, 2021
Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS techniqueCarmen Tur, Francesco Grussu, Floriana De Angelis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2019
Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI studySara Collorone, Niamh Cawley, Francesco Grussu, et al.
Brain : a Journal of Neurology|April 21, 2021
Cortical involvement determines impairment 30 years after a clinically isolated syndromeLukas Haider, Ferran Prados, Karen Chung, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2019
Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosisArman Eshaghi, Rogier A Kievit, Ferran Prados, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosisMarco Rovaris, Elda Judica, Jaume Sastre-Garriga, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2023
Do the current MS clinical course descriptors need to change and if so how? A survey of the MS communityAlan J Thompson, Marcello Moccia, Maria Pia Amato, et al.
The Lancet. Neurology|January 13, 2012
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyPeter Connick, Madhan Kolappan, Charles Crawley, et al.
Brain Communications|October 16, 2023
Genetic influences on disease course and severity, 30 years after a clinically isolated syndromeNitin Sahi, Lukas Haider, Karen Chung, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 1, 2015
DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?Steven H P van de Pavert, Nils Muhlert, Varun Sethi, et al.
Annals of Neurology|November 12, 2005
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"Chris H Polman, Stephen C Reingold, Gilles Edan, et al.
Pageof 20

Showing results (171-180 of 200) with videos related to

Sort By:
Pageof 20
Neuroimage. Clinical|December 7, 2021
Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS techniqueCarmen Tur, Francesco Grussu, Floriana De Angelis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2019
Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI studySara Collorone, Niamh Cawley, Francesco Grussu, et al.
Brain : a Journal of Neurology|April 21, 2021
Cortical involvement determines impairment 30 years after a clinically isolated syndromeLukas Haider, Ferran Prados, Karen Chung, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2019
Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosisArman Eshaghi, Rogier A Kievit, Ferran Prados, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosisMarco Rovaris, Elda Judica, Jaume Sastre-Garriga, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2023
Do the current MS clinical course descriptors need to change and if so how? A survey of the MS communityAlan J Thompson, Marcello Moccia, Maria Pia Amato, et al.
The Lancet. Neurology|January 13, 2012
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyPeter Connick, Madhan Kolappan, Charles Crawley, et al.
Brain Communications|October 16, 2023
Genetic influences on disease course and severity, 30 years after a clinically isolated syndromeNitin Sahi, Lukas Haider, Karen Chung, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 1, 2015
DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?Steven H P van de Pavert, Nils Muhlert, Varun Sethi, et al.
Annals of Neurology|November 12, 2005
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"Chris H Polman, Stephen C Reingold, Gilles Edan, et al.
Pageof 20